Lu D, Kalafatis M, Mann K G, Long G L
Department of Biochemistry, University of Vermont, College of Medicine, Burlington.
Blood. 1994 Aug 1;84(3):687-90.
Clinical manifestations of arterial and venous thrombosis in a family with protein C deficiency was associated with two mutations in the light chain of protein C: Glu20-->Ala and Val34-->Met. Further studies showed that the mutation Glu20-->Ala which eliminated a gamma-carboxylation site was exclusively responsible for the anticoagulant defect of activated protein C (APC). Membrane-bound human factor Va is inactivated by APC after two sequential cleavages of the heavy chain at Arg506 and Arg306. Human factor Va inactivation by human recombinant APC (rAPC) and a mutant molecule with an alanine instead of a glutamic acid at position 20 (rAPC(gamma 20A)) was investigated in the presence and absence of phospholipid vesicles. During a 2-hour incubation period of the cofactor with either rAPC or rAPC(gamma 20A). In the absence of a membrane surface, factor Va is cleaved quantitatively at Arg506 and retains approximately 60% of its initial cofactor activity. After a 2-hour incubation period with rAPC membrane-bound factor Va has no cofactor activity, whereas in the presence of a membrane surface and rAPC(gamma 20A) factor Va retains 60% of its initial cofactor activity. The completed loss in factor Va cofactor activity upon incubation of the membrane-bound cofactor with phospholipid vesicles and rAPC is associated with cleavages at Arg506 and Arg306, whereas membrane-bound factor Va cleavage at Arg306 by rAPC(gamma 20A) is impaired, resulting in a cofactor that is cleaved at Arg506. Slow cleavage at Arg306 occurs when membrane-bound factor Va is incubated with rAPC(gamma 20A) and only small amounts of fragments of M(r) = 45,000 and 30,000 are noticed. Our data show that the genetic defect which leads to the absence of a gamma-carboxylation site at Glu20 impairs membrane binding of human APC, which in turn is required for cleavage of factor Va at Arg306 and inactivation of the cofactor. The consequence of impaired membrane-dependent cleavage at Arg306 is manifested in vivo by venous and arterial thrombosis.
一个蛋白C缺乏家族中动脉和静脉血栓形成的临床表现与蛋白C轻链中的两个突变有关:Glu20→Ala和Val34→Met。进一步研究表明,消除γ-羧化位点的Glu20→Ala突变是活化蛋白C(APC)抗凝缺陷的唯一原因。膜结合的人因子Va在重链的Arg506和Arg306处连续两次裂解后被APC灭活。在有和没有磷脂囊泡的情况下,研究了人重组APC(rAPC)和在第20位带有丙氨酸而非谷氨酸的突变分子(rAPC(γ20A))对人因子Va的灭活作用。在辅因子与rAPC或rAPC(γ20A)共同孵育2小时期间。在没有膜表面的情况下,因子Va在Arg506处被定量裂解,并保留其初始辅因子活性的约60%。与rAPC膜结合的因子Va在孵育2小时后没有辅因子活性,而在有膜表面和rAPC(γ20A)的情况下,因子Va保留其初始辅因子活性的60%。膜结合的辅因子与磷脂囊泡和rAPC孵育后,因子Va辅因子活性的完全丧失与Arg506和Arg306处的裂解有关,而rAPC(γ20A)对膜结合因子Va在Arg306处的裂解受损,导致一个在Arg506处被裂解的辅因子。当膜结合因子Va与rAPC(γ20A)孵育时,Arg306处的裂解缓慢,仅观察到少量分子量为45,000和30,000的片段。我们的数据表明,导致Glu20处缺乏γ-羧化位点的遗传缺陷损害了人APC的膜结合,而这反过来又是因子Va在Arg306处裂解和辅因子失活所必需的。Arg306处膜依赖性裂解受损的后果在体内表现为静脉和动脉血栓形成。